Amgen Announces Launch Of Blood Counts™ And Collaboration With StoryCorps To Record And Share Stories Of Those Impacted By Multiple Myeloma Dec 2, 2016 04:00PM
Amgen (AMGN), Allergan (AGN) Announce Submission of ABP 215 MAA to EMA Dec 2, 2016 09:01AM
Amgen And Allergan Submit Biosimilar Marketing Authorization Application To European Medicines Agency For ABP 215, A Biosimilar Candidate To Bevacizumab Dec 2, 2016 09:00AM
Amgen To Present At The Citi 2016 Global Healthcare Conference Dec 1, 2016 04:00PM
Amgen (AMGN), Cytokinetics (CYTK) Announce Publication of Significant Omecamtiv Mecarbil Phase 2 Data Dec 1, 2016 06:36AM
View Older Stories

Nov 30, 2016 06:31PM The Lancet Publishes Results From COSMIC-HF Trial Showing Omecamtiv Mecarbil Significantly Improved Cardiac Function In Patients With Chronic Heart Failure
Nov 30, 2016 06:30PM The Lancet Publishes Results From COSMIC-HF Trial Showing Omecamtiv Mecarbil Significantly Improved Cardiac Function in Patients With Chronic Heart Failure
Nov 30, 2016 10:00AM Amgen Announces Presentation Of New Data In Acute Lymphoblastic Leukemia, Multiple Myeloma And Immune Thrombocytopenia At ASH 2016
Nov 21, 2016 11:34AM Arrowhead Research (ARWR) Reports Closing of License and Collaboration Agreement with Amgen (AMGN) on RNAi ARC-LPA Program
Nov 16, 2016 04:30PM Amgen (AMGN) Announces Erenumab Phase 3 Met Primary Endpoint as Migraine Treatment
Nov 16, 2016 04:30PM Amgen Announces Erenumab Significantly Reduces Monthly Migraine Days In Patients With Episodic Migraine In Second Phase 3 Study
Nov 15, 2016 04:01PM Amgen (AMGN) , Allergan (AGN) Submit Biosimilar BLA for ABP 215
Nov 15, 2016 04:00PM Amgen And Allergan Submit Biosimilar Biologics License Application For ABP 215 To U.S. Food And Drug Administration
Nov 15, 2016 12:46PM Amgen (AMGN) Announces Significant Data for Repatha in Regressing CAD-Related Atherosclerosis
Nov 15, 2016 12:28PM Repatha® (Evolocumab) Regresses Atherosclerosis In Patients With Coronary Artery Disease
Nov 14, 2016 09:00AM New 'Ten To Watch' List Highlights Top Amgen Scholars Poised To Impact The Future Of Science And Medicine
Nov 14, 2016 06:55AM Amgen (AMGN), UCB Announce Significant Data from Phase 3 BRIDGE Study for Increasing BMD in Men With Osteoporosis
Nov 12, 2016 04:30PM Results From Phase 3 BRIDGE Study Show Romosozumab Significantly Increases Bone Mineral Density In Men With Osteoporosis
Nov 11, 2016 04:01PM Amgen (AMGN) Reports EC Approval for Parsabiv to Treat sHPT in Adults with CKD
Nov 11, 2016 04:00PM European Commission Approves Parsabiv™ (etelcalcetide) For The Treatment Of Secondary Hyperparathyroidism In Adults On Hemodialysis
Nov 10, 2016 04:00PM Amgen To Webcast Investor Meeting At Upcoming American Heart Association Scientific Sessions 2016
Nov 10, 2016 08:35AM Amgen (AMGN) Enters Multiple Myeloma Collaboration with Janssen
Nov 10, 2016 08:33AM Amgen Announces Collaboration With Janssen To Co-Fund Studies With KYPROLIS® (Carfilzomib) And DARZALEX® (Daratumumab) In Patients With Multiple Myeloma
Nov 7, 2016 04:00PM Data To Be Presented At ACR/ARHP 2016 Annual Meeting Show Amgen's Ongoing Commitment To Therapies For Patients With Serious Inflammatory And Bone Diseases
Nov 7, 2016 07:30AM Amgen (AMGN) Receives FDA Approval for ENBREL sBLA as Expanded Indication
Nov 4, 2016 05:26PM FDA Approves Expanded Use Of ENBREL® (etanercept) To Treat Children With Chronic Moderate-To-Severe Plaque Psoriasis
Nov 3, 2016 04:01PM Amgen To Present At The Credit Suisse 25th Annual Healthcare Conference
Nov 2, 2016 09:00AM Amgen Appoints Lori Johnston As Senior Vice President, Human Resources
Oct 31, 2016 04:17PM Amgen Highlights Repatha® (Evolocumab) GLAGOV Imaging Study Amongst Data To Be Presented At AHA Scientific Sessions 2016
Oct 27, 2016 04:01PM Amgen Reports Third Quarter 2016 Financial Results
Oct 26, 2016 02:46PM Trading Radar for 10/27: Alphabet (GOOG), Amazon (AMZN), Twitter (TWTR) Ford (F), Baidu.com (BIDU) Report
Oct 25, 2016 05:43AM Amgen (AMGN) Makes Investment in Israel-Based eHealth Ventures
Oct 25, 2016 05:30AM Amgen To Invest In Israel-Based eHealth Ventures
Oct 24, 2016 04:00PM Amgen Announces Webcast Of 2016 Third Quarter Financial Results
Oct 20, 2016 04:20PM Amgen (AMGN) Announces XGEVA vs. Zoledronic Acid Study Met Primary Endpoint; Secondary Endpoints Missed
Oct 20, 2016 04:19PM Amgen Announces Positive Top-Line Results From XGEVA® (Denosumab) Phase 3 Trial For Delay Of Bone Complications In Multiple Myeloma Patients
Oct 14, 2016 04:05PM Amgen Announces 2016 Fourth Quarter Dividend
Oct 14, 2016 04:01PM Amgen (AMGN) Adds Former DuPont CEO Kullman as Director
Oct 14, 2016 04:00PM Amgen Announces Appointment Of Ellen J. Kullman To Board Of Directors
Oct 10, 2016 09:11AM Amgen (AMGN) Announces Additional Data from Vectibix in mCRC; Increased OS Observed
Oct 10, 2016 09:09AM New Retrospective Analyses Confirm Vectibix® (Panitumumab) Treatment Provided Survival Benefit Over Chemotherapy With Or Without Bevacizumab In Metastatic Colorectal Cancer Patients With Tumors Of Le
Oct 5, 2016 04:10PM Amgen (AMGN) Plans Presentation of New IMLYGIC Combo Data in Metastatic Colorectal Cancer at ESMO 2016
Oct 5, 2016 04:10PM New Amgen Data In Melanoma And Metastatic Colorectal Cancer To Be Presented At The European Society For Medical Oncology 2016 Congress
Oct 4, 2016 04:00PM Amgen To Participate In Citi Biotech R&D Conference Call
Oct 3, 2016 04:11PM Amgen (AMGN) Announces Publication of Positive BLINCYTO Phase 1/2 Single-Arm Trial in ALL; Says 39% Achieved Complete Remission
Oct 3, 2016 04:09PM Study Results Published In Journal of Clinical Oncology Show BLINCYTO® (blinatumomab) Induced Complete Remission In Heavily Pretreated Pediatric Patients With Philadelphia Chromosome-Negative Relapse
Sep 29, 2016 07:31AM Amgen (AMGN), Arrowhead Pharma (ARWR) Enter Two Cardiovascular-Focused License, Collaboration Agreements
Sep 29, 2016 07:31AM Amgen (AMGN), Arrowhead Pharmaceuticals (ARWR) Enter Collaborations on Two Cardiovascular Therapies
Sep 29, 2016 07:30AM Amgen And Arrowhead Pharmaceuticals Announce Two Cardiovascular Collaborations
Sep 28, 2016 04:31PM Amgen (AMGN) Announces Erenumab Phase 3 Met Primary Endpoint in Migraine Prevention
Sep 28, 2016 04:30PM Amgen Announces Erenumab Significantly Reduces Monthly Migraine Days In Patients With Episodic Migraine In First Phase 3 Study
Sep 27, 2016 05:52AM Amgen (AMGN) Announces KYPROLIS Phase 3 CLARION Trial Missed Primary Endpoint
Sep 27, 2016 04:00AM Amgen Announces Top-Line Results From Phase 3 KYPROLIS® (Carfilzomib) CLARION Study In Newly Diagnosed Multiple Myeloma Patients
Sep 26, 2016 05:00PM Amgen Opens Nomination Process For LabCentral Residency
Sep 26, 2016 04:01PM Amgen (AMGN), UCB Announce FDA Acceptance of BLA For Romosozumab
View Older Stories